The Influence by Dietary Human Milk Oligosaccharide in Low Birth Weight Infants

Not Applicable

Completed

• Conditions: Low Birth Weight Infants
• Interventions: Dietary Supplement: Infant formula with Human Milk Oligosaccharide; Dietary Supplement: Infant formula without Human Milk Oligosaccharide

• Registration Number: NCT05203900
• Lead Sponsor: Meiji Co., Ltd.

Brief Summary

This study aims to investigate the concentration of various growth factors and cytokines in blood, and to examine the gut microbiota of low birth weight infants fed with formulas with or without Human Milk Oligosaccharide (HMO) supplement. Eligible low birth weight infants are allocated to two groups, Investigational formula (with HMO) or Control formula (without HMO). The subjects are taking the assigned formula when they need to be supplemented with formula. After the informed consent was obtained and eligibility was confirmed, the intervention period begins, and ends at the one-month-old medical check-up with the assessment of the various blood growth factors and cytokines, and the gut microbiota.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-12-13
• Study First Submitted: 2021-12-23
• Study First Submitted QC: 2022-01-10
• Study First Posted: 2022-01-24
• Status Verified: 2023-02
• Primary Completion: 2023-05-24
• Study Completion: 2023-05-24
• Last Update Submitted: 2023-06-29
• Last Update Posted: 2023-07-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1-1) For infants

i. Low birth weight infants (defined as a birth weight ≥1,500 g and <2,500 g) during hospitalization and may require milk powder formula as supplement.

1-2) For mothers

i. Mothers who do not find serious viral infection

ii. Mothers who are willing to provide consent for provision of study required information and specimen(s) from both mothers and infants

iii. Mothers who are willing to provide consent as infant's legally acceptable representative (LAR) 2.

Exclusion Criteria

2-1) For infants

i. Infants who receive any formulas before Informed Consent.

ii. Infants with serious infections.

iii. Infants with necrotizing enteritis.

iv. Infants with gastrointestinal perforation.

v. Infants whom the PI determines inappropriate as a study subject (e.g. inflammatory, metabolic abnormalities and difficulty in enteral feeding).

2-2) For mothers

i. Mothers the PI determines inappropriate as a study subject

ii. Mothers under 18 years old. 3. Withdrawal criteria:

A subject must be discontinued from treatment with test formula if any of the following apply:

i. If the mother, who is a subject of the study as well as infant's LAR , asks for withdrawal from the study or withdraws consent.

ii. When a serious adverse event occurs.

iii. When an adverse event occurs, and the PI or co-investigator determines that the study should be discontinued.

iv. If it is decided that there is a risk of compromising the safety of the study subject.

v. If a subject is found to be ineligible after the start of the study.

vi. If it is found that there is a serious or continued non-compliance with the study protocol by a study subject.

vii. In addition, if the PI decides to end the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Investigational formula	Infant formula with Human Milk Oligosaccharide	Infant formula with Human Milk Oligosaccharide
Control formula	Infant formula without Human Milk Oligosaccharide	Infant formula without Human Milk Oligosaccharide

Primary Outcome Measures

Name	Time	Method
Cytokines concentration in infant's plasma	At one-month-old	The concentration of IFN-gamma (pg/mL), IL-1alpha (pg/mL), etc. in infant's plasma will be measured by immunoassay.
Growth factors concentration in infant's plasma	At one-month-old	The concentration of NGF-beta (pg/mL), BDNF (pg/mL), etc. in infant's plasma will be measured by immunoassay.
Infant's gut microbiota occupancy	At one-month-old	Total bacterial counts and bifidobacterial counts in stool will be measured by RT-PCR (copy/g wet feces). Occupancy of microbiota in infant's stool will be comprehensively analyzed by DNA/RNA Sequencing (percent).

Trial Locations

Locations (1)

King Chulalongkorn Memorial Hospital; 🇹🇭 Bangkok, Thailand